PL1896006T3 - Sposób wytwarzania granulek zawierających entakapon do postaci dawkowania doustnego - Google Patents

Sposób wytwarzania granulek zawierających entakapon do postaci dawkowania doustnego

Info

Publication number
PL1896006T3
PL1896006T3 PL06755404T PL06755404T PL1896006T3 PL 1896006 T3 PL1896006 T3 PL 1896006T3 PL 06755404 T PL06755404 T PL 06755404T PL 06755404 T PL06755404 T PL 06755404T PL 1896006 T3 PL1896006 T3 PL 1896006T3
Authority
PL
Poland
Prior art keywords
entacapone
oral dosage
manufacturing
dosage forms
containing granules
Prior art date
Application number
PL06755404T
Other languages
English (en)
Inventor
Kari Vahervuo
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37400847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1896006(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of PL1896006T3 publication Critical patent/PL1896006T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06755404T 2005-06-08 2006-06-07 Sposób wytwarzania granulek zawierających entakapon do postaci dawkowania doustnego PL1896006T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68833405P 2005-06-08 2005-06-08
EP06755404A EP1896006B1 (en) 2005-06-08 2006-06-07 A manufacturing method for entacapone-containing granules for oral dosage forms
PCT/FI2006/000182 WO2006131591A2 (en) 2005-06-08 2006-06-07 An entacapone-containing oral dosage form

Publications (1)

Publication Number Publication Date
PL1896006T3 true PL1896006T3 (pl) 2010-03-31

Family

ID=37400847

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06755404T PL1896006T3 (pl) 2005-06-08 2006-06-07 Sposób wytwarzania granulek zawierających entakapon do postaci dawkowania doustnego

Country Status (19)

Country Link
US (3) US20080187590A1 (pl)
EP (5) EP2335696A1 (pl)
JP (2) JP5336181B2 (pl)
KR (2) KR101617990B1 (pl)
CN (1) CN101184483B (pl)
AT (1) ATE444746T1 (pl)
AU (1) AU2006256724B2 (pl)
CA (1) CA2611114C (pl)
CY (1) CY1109587T1 (pl)
DE (1) DE602006009652D1 (pl)
DK (1) DK1896006T3 (pl)
EA (1) EA013161B1 (pl)
ES (1) ES2311442T3 (pl)
MX (1) MX2007015377A (pl)
NO (1) NO345046B1 (pl)
PL (1) PL1896006T3 (pl)
PT (2) PT2050447T (pl)
SI (1) SI1896006T1 (pl)
WO (1) WO2006131591A2 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
WO2008081268A2 (en) * 2006-12-27 2008-07-10 Wockhardt Research Centre Pharmaceutical compositions of entacapone
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
ATE534382T1 (de) * 2008-02-06 2011-12-15 Wockhardt Ltd Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon
KR101444979B1 (ko) 2008-02-06 2014-10-07 욱크하르트 리미티드 생체 이용율이 개선된 엔타카폰, 레보도파 및 카르비도파의 약학 조성물
CA2734972C (en) * 2008-08-22 2017-03-28 Wockhardt Research Centre An extended release pharmaceutical composition of entacapone or salts thereof
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
JP5774610B2 (ja) 2010-03-04 2015-09-09 オリオン コーポレーション パーキンソン病の治療方法
DE102010023828A1 (de) * 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
BR112013027219A2 (pt) * 2011-04-26 2016-12-27 Innopharmax Inc composição de entacapone, processo para preparar a composição de entacapone, composição farmacêutica, e, uso da composição de entacapone
CN103845318A (zh) * 2012-12-07 2014-06-11 天津市汉康医药生物技术有限公司 恩他卡朋分散片
HUE056006T2 (hu) * 2013-03-13 2022-01-28 Neuroderm Ltd Kombináció Parkinson-kór kezelésére
ES2956840T3 (es) * 2013-08-19 2023-12-29 Taris Biomedical Llc Dispositivos de administración de fármacos de múltiples unidades
PL3777833T3 (pl) 2014-03-13 2024-03-25 Neuroderm Ltd. Kompozycje inhibitorów dekarboksylazy dopa
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
JP6411265B2 (ja) * 2015-03-30 2018-10-24 共和薬品工業株式会社 エンタカポン含有医薬組成物
AU2016259897A1 (en) * 2015-05-08 2017-08-17 Wockhardt Limited Stable pharmaceutical compositions comprising antibacterial agent
TW201717947A (zh) * 2015-08-20 2017-06-01 漢達生技醫藥股份有限公司 包含氨氯地平和右美沙芬的藥物組合物
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
ES2895054T3 (es) * 2016-08-18 2022-02-17 Ilko Ilac Sanayi Ve Ticaret Anonim Sirketi Fórmula de comprimido antiparkinson con perfil de disolución mejorado
CN106236720A (zh) * 2016-08-29 2016-12-21 海南通用康力制药有限公司 一种恩他卡朋的药物组合物及其制备方法
TWI595871B (zh) * 2016-09-22 2017-08-21 生達化學製藥股份有限公司 含有兒茶酚－ｏ－甲基轉移酶抑制劑之口服醫藥組成物及其製造方法
JP6735007B2 (ja) * 2018-09-26 2020-08-05 共和薬品工業株式会社 エンタカポン含有医薬組成物
JP2023517690A (ja) * 2020-03-13 2023-04-26 ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ 微粉化オピカポン
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US20240300930A1 (en) * 2021-02-26 2024-09-12 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide
CN113274362A (zh) * 2021-03-31 2021-08-20 海南通用康力制药有限公司 恩他卡朋片的生产方法
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
GB2238047B (en) 1989-11-03 1993-02-10 Orion Yhtymae Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
US5429825A (en) * 1992-06-26 1995-07-04 Mcneil-Ppc, Inc. Rotomelt granulation
FI101039B (fi) * 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
US5562291A (en) * 1995-09-28 1996-10-08 Daniel D. Garcia Arrow tip for shooting wooden target
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
WO1998007431A1 (en) * 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
MXPA04007427A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Formulaciones de azitromicina granuladas por via seca.
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
WO2005063696A2 (de) 2003-12-31 2005-07-14 Cilag Ag Neue kristalline formen von entacapone und deren herstellung
US20060222703A1 (en) * 2005-04-01 2006-10-05 Iprbox Oy Pharmaceutical composition and preparation method thereof
EP1970055B1 (en) * 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Multi-layered tablet with triple release combination
US20090155369A1 (en) * 2007-12-13 2009-06-18 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa

Also Published As

Publication number Publication date
SI1896006T1 (sl) 2010-02-26
EP2050447A1 (en) 2009-04-22
JP5336181B2 (ja) 2013-11-06
EA200702616A1 (ru) 2008-04-28
CN101184483A (zh) 2008-05-21
EA013161B1 (ru) 2010-02-26
AU2006256724A1 (en) 2006-12-14
KR20150001843A (ko) 2015-01-06
PT2050447T (pt) 2018-01-17
WO2006131591A3 (en) 2007-03-01
EP2335696A1 (en) 2011-06-22
KR101617990B1 (ko) 2016-05-03
DE602006009652D1 (de) 2009-11-19
NO20076687L (no) 2007-12-28
CY1109587T1 (el) 2014-08-13
EP1896006B1 (en) 2009-10-07
AU2006256724B2 (en) 2012-06-07
US20130274330A1 (en) 2013-10-17
JP2013173760A (ja) 2013-09-05
EP2308487A1 (en) 2011-04-13
MX2007015377A (es) 2008-02-14
CA2611114C (en) 2014-09-23
JP2008542434A (ja) 2008-11-27
KR101468738B1 (ko) 2014-12-03
DK1896006T3 (da) 2009-12-07
EP1896006A2 (en) 2008-03-12
PT1896006E (pt) 2009-10-19
US20120289594A1 (en) 2012-11-15
ES2311442T3 (es) 2010-01-07
WO2006131591A2 (en) 2006-12-14
US20080187590A1 (en) 2008-08-07
CN101184483B (zh) 2011-08-10
CA2611114A1 (en) 2006-12-14
EP2050447B1 (en) 2017-10-11
KR20080012945A (ko) 2008-02-12
ATE444746T1 (de) 2009-10-15
ES2311442T1 (es) 2009-02-16
NO345046B1 (no) 2020-09-07
EP2316448A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
SI1896006T1 (sl) Postopek za izdelavo granul, ki vsebujejo entakapon, za oralne odmerne oblike
TWI449540B (en) Process for the production of an abuse-proofed dosage form
ZA200800397B (en) Solid dosage forms of valsartan and amiodipine and method of making the same
ME01599B (me) Postupak za dobijanje dihidropteridinona
PL1993985T3 (pl) Sposób wytwarzania 1,2-propanodiolu
IL172469A0 (en) Methods for the production of insulin plants
PL1855882T3 (pl) Nowe oznakowanie i sposób jego wytwarzania
UA92894C2 (ru) Способ приготовления и применения композиции адсорбента фосфата, адсорбент фосфата, композиция адсорбента фосфата
TWI346402B (en) Method for the production of a luminesence-diode chip and luminesence-diode chip
WO2007025146A3 (en) Balsalazide formulations and manufacture and use thereof
PL370131A1 (pl) Sposób wytwarzania nawozu zawierającego azotan wapnia
SI1794111T1 (sl) Postopek za pridobivanje ciklopentanona
GB0415076D0 (en) Process for the preparation of gabapentin
PL370009A1 (pl) Sposób wytwarzania S-(-)-1,2,3,4-tetrahydro-2-naftolu
PL366493A1 (pl) Sposób wytwarzania S-(-)-1,2,3,4-tetrahydro-2-naftolu
WO2006089651A3 (de) Trofosfamid-haltige filmtabletten und verfahren zu deren herstellung
PL376036A1 (pl) Sposób otrzymywania paliwa brykietowanego
PL377671A1 (pl) Sposób wytwarzania kwasu 2,4- dichlorofenoksyoctowego oraz jego soli
PL372012A1 (pl) Sposób wytwarzania chlorku N-metylonikotynamidu
PL372014A1 (pl) Sposób wytwarzania kwasu 1-metylo-4-nitro-3-n-propylo-pirazolo-5-karboksylowego
PL369540A1 (pl) Sposób wytwarzania symetrycznych mezo-tetraaryloporfiryn
PL373928A1 (pl) Sposób wytwarzania imatinibu
PL378375A1 (pl) Sposób wytwarzania nanoceramik BaTiO₃
PL378004A1 (pl) Sposób wytwarzania R-pantolaktonu
PL369805A1 (pl) Sposób wytwarzania paszowych wodorofosforanów wapnia